| Literature DB >> 27152704 |
Rebecka Vyth1, Amy Leval1,2, Björn Eriksson1,2, Eva-Lena Ericson3, Lena Marions4, Maria-Pia Hergens1,2.
Abstract
Gonorrhoea incidence has increased substantially in Stockholm during the past years. These increases have coincided with changes in testing practice from solely culture-based to nucleic acid amplification tests (NAAT). Gonorrhoea NAAT is integrated with Chlamydia trachomatis testing and due to opportunistic screening for chlamydia, testing prevalence for gonorrhoea has increased substantially in the Stockholm population. The aim of this study was to examine epidemiological risk-factors for discordant case which are NAAT positive but culture negative. These discordant cases are especially problematic as they give rise to diagnostic and treatment uncertainties with risk for subsequent sequelae. All gonorrhoea cases from Stockholm county during 2011-2012 with at least one positive N. gonorrhoea NAAT test and follow-up cultures were included (N = 874). Data were analysed using multivariate and stratified logistic regression models. Results showed that women were 4-times more likely (OR 4.9; 95% CI 2.4-6.7) than men to have discordant cultures. Individuals tested for gonorrhoea without symptoms were 2.3 times more likely (95% CI 1.5-3.5) than those with symptoms to be discordant. NAAT method and having one week or more between NAAT and culture testing were also indicative of an increased likelihood for discordance. Using NAAT should be based on proper clinical or epidemiological indications and, when positive, followed-up with a culture-based test within one week if possible. Routine gonorrhoea testing is not recommended in low prevalence populations.Entities:
Mesh:
Year: 2016 PMID: 27152704 PMCID: PMC4859506 DOI: 10.1371/journal.pone.0155017
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Trends in gonorrhoea, Stockholm region 2000–201.
Descriptive information on gonorrhea NAAT positive cases included in the study. 2011–2012.
| Culture neg n (%) | Culture pos n (%) | Total | |
|---|---|---|---|
| 289 | 585 | 874 | |
| Men | 98 (20%) | 403 (80%) | 501 |
| Women | 191 (51%) | 182 (49%) | 373 |
| < 20 yrs | 54 (39%) | 86(61%) | 140 |
| 20–29 yrs | 151(35%) | 287 (65%) | 429 |
| 30–39 yrs | 53 (32%) | 113 (68%) | 166 |
| 40- yrs | 31 (22%) | 108 (78%) | 139 |
| Yes | 41 (30%) | 95 (70%) | 136 |
| No | 248 (34%) | 490 (66%) | 738 |
| Yes | 131 (22%) | 456 (78%) | 587 |
| No | 123 (51%) | 120 (49%) | 243 |
| Missing | 35 (80%) | 9 (20%) | 44 |
| Symptoms | 117 (23%) | 381 (77%) | 498 |
| Contact tracing | 68 (44%) | 86 (56%) | 154 |
| Risk group | 33 (24%) | 102 (76%) | 135 |
| Becton Dickinson SDA | 248 (36%) | 449 (64%) | 697 |
| Abbott Real Time | 16 (24%) | 51 (76%) | 67 |
| Roche Cobas 4800 | 25 (23%) | 83 (77%) | 108 |
| Missing | 0 | 2 (100%) | 2 |
| < 7 days | 108 (20%) | 444 (80%) | 552 |
| 7- days | 103 (42%) | 141 (58%) | 244 |
| Missing | 78 (100%) | 78 | |
| Homosexual transmission | 36 (17%) | 182 (83%) | 218 |
| Heterosexual transmission | 45 (17%) | 214 (83%) | 259 |
| Missing/other | 17 (71%) | 7 (29%) | 24 |
a Row percent shown
b Among women there was no homosexual transmission reported
Multivariate logistic regression modeling risks for gonorrhea NAAT positive, culture negative cases, presented as odds ratios with 95% confidence intervals.
| OR | (95% CI) | OR | (95% CI) | OR | (95% CI) | ||
|---|---|---|---|---|---|---|---|
| Men | 98 | ref | ref | ||||
| Women | 191 | 4.3 | (3.2–5.8) | 4.0 | (2.4–6.7) | 5.3 | (3.1–9.2) |
| < 20 yrs | 54 | ref | ref | ||||
| 20–29 yrs | 151 | 0.9 | (0.6–1.3) | 1.6 | (1.0–2.7) | 1.8 | (1.0–3.3) |
| 30–39 yrs | 53 | 0.7 | (0.5–1.2) | 1.8 | (0.9–3.6) | 1.8 | (0.8–3.7) |
| 40- yrs | 31 | 0.5 | (0.3–0.8) | 1.6 | (0.8–3.4) | 1.6 | (0.7–3.4) |
| No | 248 | ref | ref | ||||
| Yes | 41 | 0.9 | (0.6–1.3) | 0.8 | (0.5–1.4) | 0.8 | (0.5–1.4) |
| Yes | 131 | ref | ref | ||||
| No | 123 | 3.6 | (2.6–4.9) | 2.3 | (1.5–3.5) | ||
| Symptoms | 117 | Ref | |||||
| Contact tracing | 68 | 2.6 | 2.5 | (1.6–2.7) | |||
| Risk group | 35 | 1.1 | 0.8 | (0.4–1.3) | |||
| Becton Dickinson SDA | 248 | ref | ref | ||||
| Abbott Real Time | 16 | 0.6 | (0.3–1.0) | 0.4 | (0.2–0.9) | 0.4 | (0.2–1.0) |
| Roche Cobas 4800 | 25 | 0.5 | (0.3–0.9) | 0.3 | (0.1–0.5) | 0.3 | (0.1–0.6) |
| < 7 days | 108 | ref | ref | ||||
| 7- days | 103 | 3.0 | (2.2–4.2) | 2.6 | (1.7–4.0) | 2.5 | (1.6–3.9) |
| Heterosexual transmission | 45 | ref | ref | ||||
| Homosexual transmission | 36 | 0.4 | (0.2–0.5) | 1.1 | (0.6–2.7) | 1.6 | (0.8–2.9) |
a Univariate model
b Multivariate model including, sex, age group, chlamydia co-infection, symptoms, NAAT method, days between NAAT and culture and mode of transmission
c Multivariate model including, sex, age group, chlamydia co-infection, reason for testing, NAAT method, days between NAAT and culture and mode of transmission
Stratified multivariate analyses modeling risks for gonorrhea NAAT positive, culture negative cases, presented as odds ratios with 95% confidence intervals.
| WOMEN | MEN | |||||||
|---|---|---|---|---|---|---|---|---|
| Nr | OR | OR | OR | Nr | OR | OR | OR | |
| < 20 yrs | 49 | ref | ref | ref | 5 | ref | ref | ref |
| 20–29 yrs | 109 | 1.5 (1.0–2.4) | 1.6 (0.9–2.8) | 2.3 (1.1–3.7) | 42 | 1.1 (0.4–3.1) | 1.8 (0.3–9.2) | 1.7 (0.3–8.6) |
| 30–39 yrs | 23 | 1.8 (0.9–3.8) | 1.7 (0.7–4.0) | 1.5 (1.5–4.3) | 30 | 1.5 (0.5–4.2) | 2.4 (0.4–13.4) | 2.0 (0.4–10.9) |
| 40- yrs | 10 | 0.9 (0.4–2.2) | 0.6 (0.2–1.9) | 0.8 (0.2–2.8) | 21 | 1.1 (0.4–3.1) | 3.1 (0.6–17.4) | 2.5 (0.5–13.3) |
| No | 165 | ref | ref | ref | 83 | ref | ref | ref |
| Yes | 26 | 0.6 (0.4–1.1) | 0.7 (0.3–1.3) | 0.8 (0.4–1.65) | 15 | 1.1 (0.6–2.0) | 1.0 (0.4–2.3) | 0.8 (0.3–1.9) |
| Yes | 82 | ref | ref | 49 | ref | ref | ||
| No | 87 | 1.4 (0.9–2.1) | 1.4 (0.8–2.2) | 36 | 6.1 (3.6–10.4) | 6.6 (3.3–13.3) | ||
| Symptoms | 72 | ref | ref | 45 | ref | ref | ||
| Contact tracing | 20 | 0.4 (0.2–0.7) | 0.4 (0.2–0.8) | 13 | 1.9 (1.0–3.9) | 2.1 (0.9–5.1) | ||
| Risk group | 48 | 1.2 (0.7–2.0) | 1.2 (0.6–2.2) | 20 | 3.1 (1.7–5.7) | 3.0 (1.3–6.6) | ||
| Becton Dickinson SDA | 161 | ref | ref | ref | 87 | ref | ref | ref |
| Roche Cobas 4800 | 17 | 0.3 (0.2–0.5) | 0.2(0.1–0.4) | 0.2(0.1–0.5) | 8 | 0.3 (0.1–1.1) | 0.7 (0.2–2.3) | 0.7 (0.2–2.2) |
| Abbott Real Time | 13 | 0.5 (0.3–1.1) | 0.5 (0.2–1.2) | 0.5 (0.2–1.4) | 3 | 0.8 (0.4–1.7) | 0.3 (0.1–1.5) | 0.2 (0.02–1.7) |
| < 7 days | 63 | ref | ref | ref | 45 | ref | ref | ref |
| 7- days | 78 | 1.3 (0.9–2.1) | 1.7 (1.0–2.8) | 1.5 (0.9–2.6) | 25 | 3.7 (2.1–6.5) | 6.3 (3.0–13.1) | 5.9 (2.8–12.3) |
| Heterosexual transmission | 45 | ref | ref | ref | ||||
| Homosexual transmission | 36 | 0.9 (0.6–1.5) | 1.2 (0.6–2.6) | 1.9 (0.9–3.9) | ||||
a Number of cases
bUnivariate model
c Multivariate model including, sex, age group, chlamydia co-infection, symptoms, NAAT method, days between NAAT and culture and mode of transmission
d Multivariate model including, sex, age group, chlamydia co-infection, reason for testing, NAAT method, days between NAAT and culture and mode of transmission
* Among women there were no homosexual transmission reported